IL6 and hereditary clear cell renal cell carcinoma: Recent studies have also reached consistent conclusions, such as elevated IL-6 levels, suggesting a poor response to pembrolizumab therapy in advanced renal cell carcinoma treatment, as well as worse survival outcomes (46).